Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,920,746
  • Shares Outstanding, K 104,787
  • Annual Sales, $ 1,902 M
  • Annual Income, $ 235,240 K
  • EBIT $ -124 M
  • EBITDA $ -127 M
  • 60-Month Beta 0.39
  • Price/Sales 0.82
  • Price/Cash Flow 7.52
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 104.58% (+4.49%)
  • Historical Volatility 77.23%
  • IV Percentile 82%
  • IV Rank 40.49%
  • IV High 193.83% on 07/24/25
  • IV Low 43.86% on 02/28/25
  • Expected Move (DTE 2) 0.86 (4.78%)
  • Put/Call Vol Ratio 1.41
  • Today's Volume 709
  • Volume Avg (30-Day) 3,814
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 123,087
  • Open Int (30-Day) 133,016
  • Expected Range 17.10 to 18.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.03
  • Number of Estimates 6
  • High Estimate -0.09
  • Low Estimate -1.88
  • Prior Year 1.50
  • Growth Rate Est. (year over year) -168.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.90 +6.30%
on 02/05/26
24.68 -27.23%
on 01/26/26
-5.87 (-24.63%)
since 01/09/26
3-Month
15.94 +12.67%
on 11/19/25
24.68 -27.23%
on 01/26/26
-0.02 (-0.11%)
since 11/11/25
52-Week
10.41 +72.44%
on 07/24/25
111.21 -83.85%
on 02/14/25
-91.72 (-83.63%)
since 02/11/25

Most Recent Stories

More News
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes...

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026

SRPT : 17.96 (-2.02%)
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ...

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast...

SRPT : 17.96 (-2.02%)
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025 Preliminary...

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference...

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee...

SRPT : 17.96 (-2.02%)
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a...

SRPT : 17.96 (-2.02%)
Is Biogen Stock Outperforming the Dow?

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

SRPT : 17.96 (-2.02%)
$DOWI : 50,121.40 (-0.13%)
BIIB : 191.20 (+1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 19.47
2nd Resistance Point 18.97
1st Resistance Point 18.46
Last Price 17.96
1st Support Level 17.45
2nd Support Level 16.95
3rd Support Level 16.44

See More

52-Week High 111.21
Fibonacci 61.8% 72.70
Fibonacci 50% 60.81
Fibonacci 38.2% 48.92
Last Price 17.96
52-Week Low 10.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar